

**DANIEL H. FARKAS, PhD, HCLD, FACB, CC, CLSp(MB)**

*Curriculum Vitae*

**I. General Biographical Information**

**A. Personal**

1. Name: Daniel H. Farkas
2. Date of Birth: ---; Citizenship: ---
3. Education
  - a. Undergraduate: BS, Microbiology and Public Health, Michigan State University, East Lansing, Michigan.
  - b. Graduate: PhD, Department of Cellular and Molecular Biology, Roswell Park Memorial Institute Graduate Division of the State University of New York at Buffalo. Dissertation: Sequences in the HSV-1 Genome that Inhibit Formation of Stable Biochemical Transformants. Advisor: ---.
  - c. Postgraduate Fellowship: Postdoctoral Research Scientist, Department of Molecular and Genetic Toxicology-Environmental Health Laboratory, Monsanto Agricultural Company, St. Louis, Missouri. Established and organized departmental molecular biology laboratory; surveyed oncogene activation and tumor induction caused by different chemical carcinogens.

**B. Academic Appointments**

1. Current Faculty Positions: Associate Professor of Pathology, Baylor College of Medicine
2. Previous Faculty Positions
  - a. Adjunct Associate Professor. Department of Medical Technology, Michigan State University, East Lansing, Michigan. 1995-1998
  - b. Adjunct Assistant Professor. Department of Medical Technology, Michigan State University, East Lansing, Michigan. 1992-1995
  - c. Clinical Instructor, Medical Technology Training Program, School of Medical Technology, Department of Clinical Pathology, William Beaumont Hospital, Royal Oak, Michigan. 1991-1998
3. Current courtesy faculty appointments at other institutions: none

**C. Other advanced training/experience**

1. Formal sabbatic leave: none
2. Other specialized training following academic appointment: none (see appendix one-“Continuing education”)

**D. Other Information**

1. Honors or Awards
  - a. AACC Outstanding Speaker Award, 2000
  - b. AACC Molecular Pathology Division Past Chairman’s Award, presented July 30, 1996; Chicago, Illinois
  - c. Sigma Xi Poster Competition Winner: “Inhibition of Transformation by HSV DNA,” April 30, 1986. Buffalo, New York
2. Board Certification
  - a. High Complexity Clinical Laboratory Director-HCLD in Molecular Diagnostics. Certification credential from the American Board of Bioanalysis, St. Louis, Missouri. Examinations in general laboratory knowledge and clinical molecular biology taken and passed in Boston, Massachusetts, ---

- b. Clinical Consultant in Molecular Diagnostics. Certification credential from the American Board of Bioanalysis, St. Louis, Missouri in ---
  - c. Certified Laboratory Specialist in Molecular Biology-CLSp(MB). Certification credential from the National Certification Agency for Medical Laboratory Personnel, Lenexa, Kansas in ---
3. Other non-academic positions
- a. 1998-2002: Director, Clinical Diagnostics, Motorola Life Sciences (Clinical Micro Sensors before June 23, 2000), Pasadena, California. Development of chip-based molecular diagnostics (human and industrial) applications; educating the molecular diagnostics community about bioelectronic DNA detection technology; recruiting applications opportunities
  - b. 2000-2002: Director, Assay Development Department, Motorola Life Sciences (Clinical Micro Sensors before June 23, 2000). Led group of fifteen to develop chip-based assays

## II. Research Information

### A. Research Support

- 1. Department of Health and Human Services Public Health Service, Small Business Research Program: "Ultrasensitive Chemiluminescent Enzyme-Linked Assays", H Akhavan-Tafti, principal investigator for Lumigen, Inc. DH Farkas and William Beaumont Hospital, sub-contractors. 9/95-8/97
- 2. ---"Trans-acting Genes of HSV-1 that Inhibit Formation of Stable  $\text{tk}^+$  Transformants", --, DH Farkas, Co-principal Investigators. 7/86-4/87
- 3. ---"Are There Mammalian Sequences in the T-DNA of *Agrobacterium tumefaciens*?", ---, DH Farkas, Co-principal Investigators. 9/84-3/85
- 4. ---"Transfer of the Human OTC Gene to Cultured Mouse Fibroblasts", DH Farkas, Principal Investigator, ---, Co-principal Investigator. 3/83-6/83
- 5. ---graduate stipend
- 6. ---graduate stipend

### B. National Scientific Participation

- 1. Journal Editorial Boards
  - a. 2004-present, *Journal of Molecular Diagnostics*, ---
  - b. 2003-present, *Biotechnology Healthcare*, ---
  - c. 1994-present: Member, Editorial Board-*Diagnostic Molecular Pathology, The American Journal of Surgical Pathology, Part B*, ---
  - d. 1999-2002: Member, Editorial board, *IVD Technology*
  - e. 1995-present: Member, Editorial Board-*Molecular Diagnosis*, ---
  - f. 1995-1999: Member, Board of Editors-*Clinical Laboratory News*, American Association for Clinical Chemistry, ---
- 2. Review panels, invited reviewer, etc.
  - a. 2003: Review panel, *Human Pathology*
  - b. 2003: Invited reviewer, *BioTechniques*
  - c. 2003: Invited Reviewer, *Laboratory Investigation*
  - d. 2002: Invited reviewer, *Journal of Clinical Microbiology*
  - e. 2002: Invited reviewer, *Expert Review of Molecular Diagnostics*
  - f. Molecular Pathology Protocols. A Killeen, ed. *Clinical Chemistry*. 47(6):1139, 2001
  - g. Sexually Transmitted Diseases: Methods and Protocols. *Laboratory Medicine*. March, 2000
  - h. Molecular Pathology: Approaches to Diagnosing Disease in the Clinical Laboratory. R Heim, L Silverman, eds. *Clinical Chemistry*. 1995;41:637-638
  - i. 2002: Invited reviewer, *Trends in Molecular Medicine*
  - j. 2002: Invited reviewer, *Journal of Clinical Microbiology*

- k. 1997-1999: Invited reviewer, *Archives of Pathology and Laboratory Medicine* and the ASCP Press
  - l. 1997: Invited reviewer, College of American Pathologists Publications Committee-*The Criminal Investigator's Guide to DNA Evidence*
  - m. 2001-2003: Reviewer and Item Writer for the American Board of Bioanalysis Clinical Molecular Biology Examination
  - n. 1995: Invited reviewer for the Check Sample Program of the American Society of Clinical Pathologists
  - o. 1994-present: Invited reviewer (book and manuscripts), *Clinical Chemistry*, the journal of the AACC
  - p. 1994: Reviewer, AACC Request for Proposals: The Costs and Effectiveness of Laboratory Tests
  - q. 1993-5: Reviewer, William Beaumont Hospital Research Institute Grant Applications
  - r. 1993-6: Reviewer of abstracts for the AACC San Diego Conference on DNA technology
3. Professional Societies, Elected Positions, Committees and Offices Held
- a. 2004: Consultant, College of American Pathologists Point of Care Committee, Peter J. Howanitz, MD, FCAP, Chairman
  - b. 2004-2007: Appointed to a three year term on the American Board of Bioanalysis (2.1.04-1.31.07)
  - c. 2003-2004: Leader, Subcommittee on Professional Guidance of Appropriate QC as part of a CDC effort to develop QC materials for genetic testing, Joe Boone, PhD, CDC Coordinator
  - d. 2003-2004: Program Chair, Houston Society of Clinical Pathologists
  - e. 2002-2004: President-elect, President, and Past-President, respectively, Association for Molecular Pathology (AMP); member, AMP Executive Council
  - f. 2002-2006 (re-appointed in 2004 for term to run until 2007): Consultant to the Clinical and Molecular Genetics Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration, Maria Chan, PhD, Executive Secretary
  - g. Panelist, National Institute of Standards and Technology's Health Care Industry Executive Roundtable. March 31, 2003. Gaithersburg, Maryland. Dr. Arden Bement, director.
  - h. Expert panel meeting for the Duke/CDC cell line project. February 5, 2003, Raleigh-Durham, North Carolina
  - i. 2002: Observer, Subcommittee on Determining Clinical Utility of Genetic Tests, National Committee for Clinical Laboratory Standards, TJ O'Leary, MD, PhD, Chairman
  - j. 2002: Member, Industry Liaison Group for the Pharmacogenetics Research Network of the National Institute of General Medical Sciences, NIH
  - k. 2002: Chair, AMP Nominating Committee
  - l. 2002-2003: Member, AACC Nominations Committee
  - m. 2001-2003: Member, AACC Annual Meeting Organizing Committee (Plenary Sessions Organizer)
  - n. 2001-2002: Lead Advisor and Chair, IBC Conference. *The Interface: Molecular Diagnostics Meets Therapeutics*. June 2002, Boston, Massachusetts
  - o. 2001-present: Vice-chairperson, NCCLS Subcommittee on Molecular Methods for Microarrays, J Hackett, PhD, Chairperson
  - p. 2002-2006: Consultant to the Clinical and Molecular Genetics Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration, Maria Chan, PhD, Executive Secretary
  - q. 2000-2002: Industry Representative to the FDA Clinical and Molecular Genetics Panel, Geretta Wood, Executive Secretary
  - r. 2000-2002: Observer, Subcommittee on PCR-Based Assays in Molecular Hematology, National Committee for Clinical Laboratory Standards, TJ O'Leary, MD, PhD, Chairman
  - s. 2000-2001: Chair, AACC San Diego Conference on Nucleic Acids Organizing Committee
  - t. 2000-2001: Member, AACC Meetings Management Group

- u.** 1999-2000: Editor, Clinical Micro Sensors, Inc., Newsletter
- v.** 1998-1999: Secretary-Treasurer, Association for Molecular Pathology (AMP); Chair, AMP Publications Committee (*ad hoc* member: 1996-97; 2000-01)
- w.** 1998-1999: Member, AMP/ASIP Journal Oversight Committee
- x.** 1998-1999: Member, AMP/ASIP Senior Editor Selection Committee (for *The Journal of Molecular Diagnostics*)
- y.** 1998-1999: Member, Association for Molecular Pathology Journal Oversight Committee
- z.** 1998-2000: Member, AACC 2000 Annual Meeting Organizing Committee (Workshops Organizer)
- aa.** 1998: Member, Organizing Committee and Moderator for AACC Clinical Chemistry Forum on Genetic Testing, Crystal City, VA, November 3-4, 1998
- bb.** 1998: Member, Clinical Advisory Board, Qiagen, Santa Clarita, CA, February 26, 1998
- cc.** 1997-2001: Member, Government Relations Committee, American Association for Clinical Chemistry, Dr. Pennell Painter, Chair
- dd.** 1997-1998: Member, Council on Diagnostic Immunology and Molecular Pathology of the Commission on Continuing Education of the American Society of Clinical Pathologists
- ee.** 1997-1998: Legislative Liaison for the Michigan Section of AACC
- ff.** 1996-1997: *Molecular Technology for the Laboratory Professional-DNA: the Foundation of Molecular Technology*. A computer based tutorial from the National Laboratory Training Network, Nashville, Tennessee; a division of the Center for Disease Control and Prevention; assisted in preparation of text and critical review
- gg.** 1996-2002: AACC Liaison to the College of American Pathologists Molecular Pathology Resource Committee
- hh.** 1996-2001: Member, National Certification Agency for Medical Laboratory Personnel Molecular Genetics examination committee
- ii.** 1996-2001: Editor, Association for Molecular Pathology Newsletter
- jj.** 1995-1996: Member, Association for Molecular Pathology Clinical Practice Committee, Dr. Debra Leonard, Chair
- kk.** 1995-1996: Chair, Clinical Advisory Board, Visible Genetics, Toronto, Ontario, Canada
- ll.** 1995-1997: Member, Scientific Advisory Board, Johnson & Johnson Clinical Diagnostics, Rochester, NY
- mm.** 1995: Program Director-1995 AACC San Diego Conference: Nucleic Acids-A Decade of Discovery
- nn.** 1994-1996: Liaison (AMP) to the AACC and its Molecular Pathology Division
- oo.** 1995: Past-Chair and member, Executive Committee, AACC Molecular Pathology Division
- pp.** 1994: Invited guest, Planning Committee-1994 San Diego Conference on DNA
- qq.** 1993-1995: Consultant, College of American Pathologists Patient Preparation and Specimen Handling Editorial Board. Molecular Pathology Testing
- rr.** 1994: Chair, Molecular Pathology Division, American Association for Clinical Chemistry (Chair-elect in 1993)
- ss.** 1992: Member, Organizing Committee for "Molecular Aspects of Histocompatibility Testing", a one day symposium-Organ Procurement Agency of Michigan
- tt.** 1992-1998: Member, Organizing Committee for "DNA Technology in the Clinical Laboratory", an annual symposium at William Beaumont Hospital, Royal Oak, Michigan
- uu.** 1992-1996: Observer, Subcommittee on Molecular Hematology, National Committee for Clinical Laboratory Standards, TJ O'Leary, MD, PhD, Chairman
- vv.** 1992-1996: Contributing editor, American Association for Clinical Chemistry, Molecular Pathology Division Newsletter
- ww.** 1991-1994: Member, Scientific Committee, American Association for Clinical Chemistry, Molecular Pathology Division
- xx.** 1991-1995: Member, Executive Committee, AACC Molecular Pathology Division
- yy.** 1991-1993: Member, Organ Procurement Agency of Michigan Histocompatibility Committee
- zz.** 1991-1994: Member, William Beaumont Hospital Research Institute Common Use Committee

- aaa.** 1991-1998: Member, William Beaumont Hospital Medical Staff
- bbb.** 1989-91: Member, Saint Barnabas Medical Center Medical Staff
- ccc.** 1989-91: Member, Saint Barnabas Medical Center Radiation Protection Committee
- ddd.** 1988-89: Member, Executive Committee, Monsanto Environmental Health Lab Manual Committee
- eee.** 1987-89: Member, Monsanto New Employees Committee
- fff.** 1984-85: Student Representative, Cellular and Molecular Biology Admissions and Standings Committee, Roswell Park Memorial Institute, Buffalo, New York
- ggg.** 1980-82: Senator ('81-'82) and Alternate Senator ('80-'81), Graduate Student Association Senate-SUNY at Buffalo

PROFESSIONAL SOCIETIES:

- a.** Houston Society of Clinical Pathology (2003-present)
  - b.** Fellow of the National Academy of Clinical Biochemistry (2000-present)
  - c.** Association for Laboratory Automation (1999-2001)
  - d.** American Association for the Advancement of Science (1986-present)
  - e.** American Association for Clinical Chemistry (1990-present)
  - f.** American Association of Bioanalysts (1997-present)
  - g.** American Society of Clinical Pathologists (1991-1999)
  - h.** American Society of Microbiology (1987-1992; 1999-present)
  - i.** American Society of Human Genetics (1991-1993)
  - j.** Association of Clinical Scientists (1993-1994)
  - k.** Association of Molecular Pathology (1994-present)
  - l.** International Academy of Pathology, US-Canadian Division (1994)
  - m.** Transplantation Society of Michigan (1991-1993)
- 4.** Invited Lectures, Presentations, Research Seminars: National, International (**I**)
- a.** Moderator and Speaker, An Overview of Molecular Diagnostics, an EduTrack at the AACC Annual Meeting in Los Angeles, California, July 29, 2004
  - b.** (**I**) Perspectives on Molecular Diagnostics: Past, Present, Future. Keynote Presentation at the EF Conference on "Opportunities and Challenges: The Future of Molecular Diagnostics," June 7-8, 2004. London, England
  - c.** Introduction to Molecular Diagnostics. Houston Society of Clinical Pathologists 44<sup>th</sup> Annual Meeting. Houston, Texas, April 24, 2004
  - d.** Molecular Diagnostics: Yesterday, Today and Tomorrow. Grand Rounds. Department of Pathology. University of Texas-Houston. January 21, 2004
  - e.** Moderator and Speaker, Quality Control Materials for Genetic Tests. A CDC Conference. Atlanta, Georgia. September 15-16, 2003 and March 8, 2004
  - f.** Technologies in Molecular Diagnostics. College of American Pathologists Annual Meeting. San Diego, California. September 13, 2003
  - g.** Molecular Diagnostics: Yesterday, Today and Tomorrow. The Business and Technology of Healthcare. SG-2 The Edge Summer Meeting. Chicago, Illinois. July 17, 2003
  - h.** Molecular Pathology. Internal Medicine Service Meeting. The Methodist Hospital, June 16, 2003. Houston, Texas
  - i.** Real Time PCR Detection of Group B *Streptococcus*. Obstetrics and Gynecology Service Meeting. The Methodist Hospital, June 2, 2003. Houston, Texas
  - j.** Tools for Molecular Hematology-Oncology Applications. Lymphoma Tumor Board. The Methodist Hospital, Houston, Texas, May 19, 2003
  - k.** DNA in Laboratory Medicine. Pin Oak Middle School, Houston, Texas. May 1, 2003
  - l.** Evolving Technologies for Clinical Diagnostics. Opening Remarks. National Institute of Standards and Technology's Health Care Industry Executive Roundtable. Gaithersburg, Maryland, March 31, 2003
  - m.** Advances in Molecular Diagnostics: Bioelectronic Detection of Nucleic Acids. Baylor College of Medicine. Houston, Texas, March 12, 2002

- n.** Bioelectronic Detection of Nucleic Acids: A Platform for Molecular Diagnostics. American Pathology Foundation Semi-annual Meeting. Las Vegas, Nevada. March 9, 2002
- o.** Bioelectronic Detection of Nucleic Acids: A Platform for Molecular Diagnostics. Molecular Analysis for Research and Diagnostics. Cambridge Healthcare Institute. San Diego, California. February 13, 2002
- p.** Member, Molecular Diagnostics Expert Panel Discussion. Chips to Hits Annual Meeting. San Diego, California. October 29, 2001
- q.** Bioelectronic Detection of Nucleic Acids: A Platform for Molecular Diagnostics. Southeast Section of the American Association for Clinical Chemistry and Industrial Workshop at the AACC Annual Meeting. Chicago, Illinois. July 30 and July 31, 2001
- r.** Low Density Bioelectronic DNA Arrays: A Workshop. EuroBiochips Microarray and Microfluidics Technology Congress. Munich, Germany. June 7, 2001
- s.** Bioelectronic DNA Detection: A Platform for Pharmacogenomics and Other Diagnostic Applications. Inauguration Symposium, Laboratório Fleury, São Paulo Brazil. June 2, 2001
- t.** Bioelectronic Detection of Nucleic Acids for Clinical Laboratory Diagnostics. Cleveland Clinic. Cleveland, Ohio. May 9, 2001
- u.** Bioelectronic DNA Detection as a Platform for Clinical Laboratory Diagnostics. West Valley Laboratory Symposium. Woodland Hills, California. May 5, 2001
- v.** Bioelectronic Detection of Nucleic Acids. California Association of Public Health Laboratory Directors Annual Meeting. Newport Beach, California. April 26, 2001
- w.** Bioelectronic DNA Detection as a Platform for Clinical Laboratory Diagnostics. Kaiser Permanente Laboratory Operations Committee Meeting. Baldwin Park, California. March 28, 2001
- x.** Array-based Bioelectronic Detection of Nucleic Acids. Joint meeting of the Histochemical Society, Society for Immunohistochemistry, and the International Society for Analytical and Molecular Morphology. Santa Fe, New Mexico. February 5, 2001
- y.** A View to the Future of Molecular Diagnostic Testing. AACC Southern California Section Meeting. Anaheim, California. November 15, 2000 (for which I received an AACC Best Speaker Award)
- z.** Bioelectronic Detection of Nucleic Acids. American Society for Microbiology, Southern California Branch 64<sup>th</sup> Annual Meeting. San Diego, California. November 4, 2000
- aa.** Low Density Bioelectronic DNA Chips for Molecular Diagnostics. Advancing Pathology Information, Imaging, and the Internet 2000. UAREP Focus Session: "Pathology Informatics in Support of Molecular Medicine." Pittsburgh, Pennsylvania. October 25, 2000
- bb.** Molecular Diagnostics Using Bioelectronic Nucleic Acid Detection. California State Department of Health. Berkeley, California. October 20, 2000
- cc.** A Bioelectronic Detection Platform for Nucleic Acids. 2000 ASCP/CAP Annual Meeting. Session SA16: DNA Vision of the Future. Dr. Richard Froede, Chairperson. San Diego, California. October 15, 2000 and Philadelphia, Pennsylvania. October 22, 2001
- dd.** Molecular Diagnostics Using Bioelectronic Detection of Nucleic Acids. City of Hope Seminar Series. Duarte, California. September 19, 2000
- ee.** Detection of Nucleic Acids Using a Novel Bioelectronic Technology. Food and Drug Administration. Rockville, Maryland. May 4, 2000
- ff.** Novel Molecular Approaches to Identify Pathogens: Bioelectronic Detection of Nucleic Acids. Strategies for Identification and Characterization of Unknown Pathogens. A meeting funded by the Centers for Disease Control and Prevention, National Center for Infectious Diseases. The Banbury Center, Cold Spring Harbor Laboratory, April 2-5 2000
- gg.** Bioelectronic Detection of Nucleic Acids. International Society of Laboratory Hematology. Banff, Alberta, Canada. April 16, 2000 (**I**)
- hh.** Bioelectronic Detection of Nucleic Acids. AACC Southern California Section Meeting. Long Beach, California. March 21, 2000
- ii.** Molecular Electronics: A Versatile Platform for Nucleic Acid Detection. Laboratory Automation Annual Conference and Exhibition. Palm Springs, CA. January 24, 2000
- jj.** Bioelectronic Detection of Nucleic Acids. Medical College of Virginia. Richmond, Virginia. October 21, 1999

- kk.** Bioelectronic Detection of Nucleic Acids. A presentation of the Laboratory Society: Mayo Clinic Foundation House at the Mayo Clinic. Rochester, Minnesota. October 8, 1999
- ll.** Moderator, AACC Edutrack: "Chipping Away: What's New in Clinical Laboratory Diagnostics." AACC Annual Meeting. New Orleans, Louisiana. July 26, 1999
- mm.** DNA Diagnostics Using a Novel Electronic Reader. Myriad Genetics. Salt Lake City, Utah, May 11, 1999
- nn. (I)** (i) Molecular Diagnostics and (ii) DNA Chip Technology. Both presented at the Isala Conference on DNA Diagnostics. Isala Hospital. Zwolle, Holland. April 19-20, 1999
- oo.** Clinical Molecular Pathology-Questions and Answers. William Beaumont Hospital Eighth Annual Symposium on "DNA Technology in the Clinical Laboratory." Royal Oak, Michigan, March 26-27, 1999
- pp.** Point-of-Care Molecular Diagnostics. Technolink Association. California Institute of Technology. Pasadena, California, February 18, 1999
- qq.** Moderator, AACC Clinical Chemistry Forum on Genetic Testing, Crystal City, VA, November 3-4, 1998
- rr.** Credentials for Molecular Diagnosticians. SmithKline Beecham Clinical Laboratories, Van Nuys, California, October 14, 1998
- ss.** Clinical Molecular Pathology-Questions and Answers. Roundtable presentations at the AACC Annual meeting. Chicago, Illinois, August 3, 1998 and Atlanta, Georgia, July 23, 1997
- tt.** Diagnostic Molecular Pathology Question and Answer session. Quest Diagnostics, San Juan Capistrano, California, July 9, 1998
- uu.** Establishment of a Molecular Diagnostics Laboratory: What, When and How. Clinical Ligand Assay Society and National Academy of Clinical Biochemists Joint Meeting, Rye, New York, May 6, 1998
- vv.** The Ethics of DNA Diagnostics. Groves High School, Birmingham, Michigan, March 19, 1998
- ww.** DNA Diagnostics. Birmingham Rotary Club, Birmingham, Michigan, January 19, 1998
- xx.** Presenter, Diagnostic Immunology and Molecular Pathology Update. American Society of Clinical Pathologists Annual Meeting. Philadelphia, Pennsylvania, September 22, 1997
- yy.** What You Need to Know to Set Up Molecular Testing at Your Institution; with Dr. K. Kaul. American Society of Clinical Pathologists Annual Meeting. Philadelphia, Pennsylvania, September 21, 1997; San Diego, California, October 1, 1996; New Orleans, Louisiana, September 17, 1995
- zz.** Molecular Diagnostics in Oncology, as part of a Boehringer Mannheim Symposium on Marco Island, Florida, May 5, 1997
- aaa.** "Mainstreaming Molecular Diagnostics into Routine Microbiology" Presented as part of "Advances in Molecular Diagnostics of HIV and Other Infectious Agents", a program of Roche Molecular Systems prior to the American Society of Microbiology Meeting, Miami, Florida, May 2, 1997
- bbb.** "Molecular Biology: Review of Basic Concepts." Back to Basics-Laboratory Without Walls: Midwest Clinical Ligand Assay Society Meeting, Romulus, Michigan, April 30, 1997
- ccc.** "Home Brew DNA Testing." A roundtable presentation at the Michigan Society of Clinical Laboratory Scientists' Annual Meeting in Troy, Michigan, April 11, 1997
- ddd.** Co-director/Speaker, William Beaumont Hospital's 6th annual seminar on DNA Technology in the Clinical Laboratory: "Clinical molecular biology: basic methodology and diagnostic applications." William Beaumont Hospital, Royal Oak, Michigan, March 14-15, 1997
- eee.** Molecular Markers for Cancer: Future Prospects. Presented at the American Association for Clinical Chemistry (Michigan Section) meeting on Cancer Diagnosis and Monitoring. Ann Arbor, Michigan, March 6, 1997
- fff.** Molecular Diagnostics in Clinical Laboratory Medicine. Presented at a Molecular Diagnostics Seminar at the Winthrop-University Hospital, Mineola, New York, October 25, 1996

- ggg.** Considerations in Setting Up a DNA Analysis Laboratory. Presented at the American Association of Blood Banks Meeting, Orlando, Florida, October 13, 1996
- hhh.** Moderator, "Molecular Identification: From Present to Past." American Association for Clinical Chemistry Annual Meeting. Chicago, Illinois, August 1, 1996
- iii.** New Diagnostic Approaches for the Treatment of Chlamydial Infections. Presented at "Advances in Gynecology: Improving Outcomes. Dearborn, Michigan, June 29, 1996
- jjj.** The Future Role of Nucleic Acid Diagnostics. Part of an expert panel discussion group at Chiron Corporation, San Francisco, CA, May 7, 1996
- kkk.** PCR: Cornerstone of Molecular Pathology. Continuing Education Program of the Ohio Chapter of the Clinical Laboratory Manager's Association. Cleveland, Ohio, March 26, 1996
- lll.** Co-director/Speaker, William Beaumont Hospital's 5th annual seminar on DNA Technology in the Clinical Laboratory: "Clinical molecular biology: basic methodology and diagnostic applications." William Beaumont Hospital, Royal Oak, Michigan, March 8, 9, 1996
- mmm.** On Molecular Pathology-The William Beaumont Hospital Perspective. Lecture given at Johnson and Johnson Clinical Diagnostics, Rochester, NY, January 31, 1996
- nnn.** Lecture to Clinical Chemistry Group at the University of Windsor. Clinical Molecular Diagnostics, Windsor, Ontario, December 1, 1995 (I)
- ooo.** Clinical Molecular Pathology-Questions and Answers. Roundtable presentations at the San Diego Conference. November 21 and 22, 1996; November 17, 1995
- ppp.** Interview: NBC Local News (San Diego), discussion of ethical issues and molecular genetics testing, November 17, 1995
- qqq.** Leader and speaker, "Regulatory and Licensing Workshop." Association of Molecular Pathology Meeting. Minneapolis, Minnesota, November 10, 1995
- rrr.** Issues of Reimbursement and Certification. Presented at the 4th Annual Association for Molecular Pathology Meeting, Minneapolis, Minnesota, November 12, 1995
- sss.** College of American Pathologists' Inspector of Molecular Microbiology Laboratory at Detroit Medical Center, Detroit, Michigan, November 6, 1995
- ttt.** Chairperson, "Molecular Diagnostics", a symposium presented at the annual Clinichem Meeting of the American Association for Clinical Chemistry. Teaneck, New Jersey, October 14, 1995
- uuu.** Lecture on Molecular Diagnostics to the Volunteer Board of Directors of William Beaumont Hospital. October 9, 1995
- vvv.** Molecular Diagnostics-Today and Tomorrow, presented at Medical Data International's, "Opportunities in Diagnostic Testing: Technologies, Market Niches, and New Sites"; at the American Association for Clinical Chemistry annual meeting, Anaheim, California, July 20, 1995
- www.** Moderator, Molecular Pathology Symposium at the American Association for Clinical Chemistry Annual Meeting, Anaheim, California, July 18, 1995
- xxx.** Establishing a Molecular Diagnostics Laboratory, an AACC audioconference, June 8, 1995
- yyy.** Surviving a CAP Molecular Pathology Inspection, an AACC audioconference with Dr. Karen L. Kaul, June 22, 1995
- zzz.** Moderator, Technology Assessment: PCR/DNA Testing, at the National Committee for Clinical Laboratory Standards (NCCLS) Annual Meeting, Chicago, Illinois, March 30, 1995
- aaaa.** Co-director/Speaker, William Beaumont Hospital's 4th annual seminar on DNA Technology in the Clinical Laboratory: Clinical molecular biology: basic methodology and diagnostic applications. William Beaumont Hospital, Royal Oak, Michigan, March 10-11, 1995
- bbbb.** Joint Annual Conference of Medical Laboratory Organizations. What Every Clinical Laboratory Scientist Should Know About PCR (Basic), Orlando, Florida, March 2, 1995
- cccc.** Joint Annual Conference of Medical Laboratory Organizations. Progress in PCR (Advanced), Orlando, Florida, March 2, 1995



- dddd.** Standardization of Molecular Biology Methods for the Clinical Laboratory. Regulatory and Reimbursement Forum at Pharmacia Biotech. Uppsala, Sweden. December 12-13, 1994  
(I)
- eeee.** Establishment of a Molecular Diagnostics Laboratory. Michigan Society of Pathologists meeting. Ann Arbor, Michigan. December 10, 1994
- ffff.** Moderator, Molecular Pathology session at the American Association for Clinical Chemistry Conference, The Genetic Revolution, San Diego, California, November 19, 1994
- gggg.** Interview: Channel 7 News (Detroit), discussion of Johns Hopkins University discovery of a new class of mutations that may have utility for broad-based cancer screening, October 11, 1994
- hhhh.** Establishing and Setting up DNA Diagnostics in Hospital Laboratories. Roundtable presentation at the American Association for Clinical Chemistry Annual Meeting, New Orleans, July 21, 1994
- iiii.** Molecular Pathology Laboratory Quality Control Measures and Quality Assurance Programs. Roundtable presentation at the American Association for Clinical Chemistry Annual Meeting, New Orleans, Louisiana, July 18, 1994
- jjjj.** Participant, American Association for Clinical Chemistry panel discussion on AACC's role in Molecular Pathology. Washington, DC, June 20, 1994
- kkkk.** Establishing a Clinical Molecular Pathology Laboratory. Michigan State Medical Technologists' Meeting. Romulus, Michigan, April 29, 1994
- llll.** Director, Workshop, American Society of Clinical Pathologists Annual Meeting. Quality Control Measures and Quality Assurance Programs in the Molecular Pathology Laboratory, Seattle, Washington, April 9, 1994
- mmmm.** Co-director/Speaker, William Beaumont Hospital's 3rd annual seminar on DNA Technology in the Clinical Laboratory: "Molecular techniques and their clinical applications." William Beaumont Hospital, Royal Oak, Michigan, March 25, 1994
- nnnn.** College of American Pathologists' Inspector of Molecular Histocompatibility Laboratory at Harper Hospital of Detroit Medical Center, Detroit, Michigan, March 24, 1994
- oooo.** Director, Short Course, United States and Canadian Academy of Pathology Annual Meeting. "Quality Control in the Clinical Molecular Pathology Laboratory." San Francisco, California, March 17, 1994
- pppp.** Quantitation of HER-2/*neu* Gene Copy Number in Breast Tumor Specimens. Association of Clinical Scientists Fall Meeting. Toledo, Ohio, November 4, 1993.
- qqqq.** DNA Analysis in the Clinical Laboratory. Scientific Advisory Board Discussion Group in Rockland, Maine. FMC Bioproducts, October 25, 1993
- rrrr.** Molecular Assistance for Oncologists, lecture to Crossroads chapter of the Chemical Ligand Assay Society, University of Louisville, Kentucky, March 13, 1993
- ssss.** Co-director/Speaker, William Beaumont Hospital's 2nd annual seminar on DNA Technology in the Clinical Laboratory: Molecular Pathology Techniques and Quality Control, William Beaumont Hospital, Royal Oak, Michigan, March 1, 1993
- tttt.** Moderator, Molecular Aspects of Histocompatibility Testing, a one day symposium by the Organ Procurement Agency of Michigan, Detroit, Michigan, January 22, 1993
- uuuu.** Lecture to surgeons, oncologists, and pathologists, "HER-2/*neu* oncogene amplification/overexpression as a prognostic indicator in breast cancer: an update", William Beaumont Hospital, October 23, 1992
- vvvv.** Implementing a Molecular Pathology Laboratory: Issues and Answers, American Society of Clinical Pathologists (ASCP) Industry Sponsored evening session. ASCP annual meeting, Las Vegas, Nevada, October 13, 1992
- wwww.** Chair, Molecular Pathology Selected Topics Seminar, DNA Technology in the Clinical Laboratory, at the American Association for Clinical Chemistry Annual Meeting, Chicago, Illinois, July 23, 1992
- xxxx.** Co-director/Speaker, William Beaumont Hospital's 1st annual seminar on DNA Technology in the Clinical Laboratory: (i) Basics of clinical molecular biology and the B/T cell gene rearrangement test and (ii) HER-2/*neu* gene amplification as a prognostic indicator in breast cancer, William Beaumont Hospital, Royal Oak, Michigan, January 31, 1992

- yyyy. "Amplification of the HER-2/*neu* and other oncogenes in carcinoma of the breast", William Beaumont Hospital Anatomical Pathology Research Conference, November 18, 1991
- zzzz. Oncor, Inc., 1990 annual report participant. Gaithersburg, Maryland, Spring 1990

## C. Publications

1. Full papers (in refereed journals):
  - a. Use of Bioelectronic Sensors for Detection of Cystic Fibrosis and Hereditary Hemochromatosis Mutations During Validation of Positive Control Cell Lines for Use as Clinical Standards. SH Bernacki, DH Farkas, W Shi, V Chan, Y Liu, JC Beck, K Snow, VM Pratt, KG Monaghan, KJ Matteson, FV Schaefer, M Friez, AE Shrimpton, TT Stenzel. *Arch Pathol Lab Med.* 2003; **127**: 1565-1572.
  - b. Bioelectronic DNA Detection of Human Papillomaviruses: A Model System for Detection of Multiple Pathogens Using eSensor™. SD Vernon, DH Farkas, ER Unger, Y-P Chen, V Chan, DL Miller, WC Reeves. *BMC Infectious Diseases* 2003; **3**:12.
  - c. Electronic Detection of Nucleic Acids: A Versatile Platform for Molecular Diagnostics. RM Umek, SW Lin, J Vielmetter, RH Terbruggen, CJ Yu, JF Kayyem, H Yowanto, GF Blackburn, **DH Farkas**, and Y-P Chen. *J. Molec. Diagn.* 2001; **3**(2): 74-84.
  - d. Bioelectronic Detection of Point Mutations Using Discrimination of the H63D Polymorphism of the *Hfe* Gene as a Model. RM Umek, SS Lin, Y-P Chen, B Irvine, G Paulluconi, V Chan, Y Chong, L Cheung, J Vielmetter and **DH Farkas**. *Molecular Diagnosis.* 2000; **5**(4): 321-328.
  - e. Bioelectronic Detection of DNA and the Automation of Molecular Diagnostics. DH Farkas. *J Assoc. Laboratory Automation.* 1999; **4**(5):20-24.
  - f. Recommendations for In-House Development and Operation of Molecular Diagnostic Tests. MH Whittaker, DH Farkas, KL Kaul, AE Shrimpton, DGB Leonard. *American Journal of Clinical Pathology.* 1999; **111**(4):449-463.
  - g. Use of Molecular Diagnostic Methods for Lymphoma Staging in Bilateral Bone Marrow Biopsies. T Murphy, D Crisan, **D Farkas**. *Molecular Diagnosis.* 1997; **2**(3): 177-182.
  - h. Novel Chemiluminescent Substrate and Probe Systems for the Identification of CFAF508 Genotypes. LV Reddy, H Akhavan-Tafti, R DiSilva, R Handley, **DH Farkas**, AP Schaap. *Molecular Diagnosis.* 1997; **2**(2):113-120.
  - i. Specimen Stability for DNA-based Diagnostic Testing. **DH Farkas**, AM Drevon, FL Kiechle, RG DiCarlo, EM Heath, D Crisan. *Diagnostic Molecular Pathology.* 1996; **5**(4):227-235.
  - j. Molecular Analysis in a Patient with Waldenstrom's Macroglobulinemia Reveals a Rare Case of Biclinality. R Schulz, D David, **DH Farkas**, D Crisan. *Molecular Diagnosis.* 1996; **1**:159-166.
  - k. Specimen Collection and Storage for Diagnostic Molecular Pathology Investigation. **DH Farkas**, KL Kaul, DL Wiedbrauk, FL Kiechle. *Archives of Pathology and Laboratory Medicine.* 1996; **120**:591-596.
  - l. Mitochondrial Disorders: Methods and Specimen Selection for Diagnostic Molecular Pathology. FL Kiechle, KL Kaul, **DH Farkas**. *Archives of Pathology and Laboratory Medicine.* 1996; **120**:597-603.
  - m. Immunohistochemical Analysis of P-glycoprotein Expression in Breast Cancer: Clinical Correlations. DA Decker, LW Morris, AJ Levine, JE Pettinga, JL Grudzien, **DH Farkas**. *Annals of Clinical Laboratory Science.* 1995; **25**:52-59.
  - n. Clinical Applications of Molecular Techniques. *Laboratory Medicine.* 1994; **25**:633-636.
  - o. Detection of *bcl-2* Oncogene Rearrangement in Follicular Lymphoma: Nucleic Acid Hybridization and Polymerase Chain Reaction Compared. D Crisan, MJ Anstett, N Matta, **DH Farkas**. *Clinical Chemistry.* 1993; **39**(9):1980-1982.
  - p. Bone marrow biopsy imprint preparations: use for molecular diagnostic in leukemias. D Crisan, **DH Farkas**. *Annals of Clinical and Laboratory Science.* 1993; **23**:407-422.
  - q. The B and T cell gene rearrangement test: an overview of application and methodology. DL Schultz and **DH Farkas**. *Clinical Laboratory Science.* 1993; **6**(5):291-294.

- r. Improved Quantitation of HER-2/*neu* Gene Copy Number in Breast Tumor Derived DNA Samples. **DH Farkas**, LW McMahon, P Cai, RM Umek. *American Journal of Clinical Pathology*. 1993;**100**:444-450.
  - s. Multidrug resistance phenotype (MDR)-a potential marker of chemotherapy resistance in breast cancer? DA Decker, LW Morris, AJ Levine, JE Pettinga, JL Grudzien, **DH Farkas**. *Laboratory Medicine*. 1993;**24**:574-578.
  - t. Laboratory Analysis for HER-2/*neu* Gene Amplification and Protein Overexpression. **DH Farkas**, JC Long, R Schulz, N Matta, RM Umek. *Laboratory Medicine*. 1993;**24**:557-561.
  - u. Interlaboratory Assessment of the D1S80 AMPFLP Locus in Paternity Testing. JA Chimera, R Allen, M Eisenberg, A Eisenberg, D Endean, **DH Farkas**, *et al.* Proceedings from the Third International Symposium on Human Identification. 1992;199-204.
  - v. The Southern Blot: Application to the B/T Cell Gene Rearrangement Test. *Laboratory Medicine*. 1992;**23**:723-729.
  - w. Inhibition of Transient Gene Expression with Plasmids Encoding Herpes Simplex Virus Type 1 UL55 and Alpha Genes. T Block, R Jordan, **DH Farkas**, RG Hughes, Jr. *Journal of General Virology*. 1991;**72**:131-141.
  - x. *In situ* Staining Procedure for the Detection of Ornithine Transcarbamylase Activity in Polyacrylamide Gels. **DH Farkas**, CJ Skomra, GR Anderson, RG Hughes, Jr. *Analyt. Biochemistry*. 1987;**160**:421-428.
  - y. *Trans*-acting Sequences of HSV-1 that Inhibit Formation of Stable  $\text{tk}^+$  Transformants. **DH Farkas**, TMP Block, PB Hart, RG Hughes, Jr. *Journal of Virology*. 1987;**61**:2989-2996.
2. Accepted or in press:  
None
3. Other full papers (published without review by peer group or in preparation):
- a. Genetically Characterized Positive Control Cell Lines Derived From Residual Clinical Blood Samples. SH Bernacki, JC Beck, AK Stankovic, LO Williams, J Amos, K Snow-Bailey, DH Farkas, MJ Friez, FM Abu Hantash, KJ Matteson, K Monaghan, K Muralidharan, VM Pratt, TW Prior, F Schaefer, A Shrimpton, E Spector, C Stolle, C Strom, S Thibodeau, EC Cole, BK Goodman, TT Stenzel. Submitted for publication (Clinical Chemistry). December 2003.
  - b. SWOT Analysis for Molecular Diagnostics: Strengths, Weaknesses, Opportunities and Threats. DH Farkas and DW Bernard. *Biotechnology Healthcare*.
4. Abstracts given during the last three years:
- a. Recipient and donor  $t(14;18)$  in bone marrow transplant for follicular lymphoma. D McGregor, **DH Farkas**, B Schur, C Chang. Association for Molecular Pathology Annual Meeting, November 21-23, 2003. Orlando, Florida. *J Molec Diagn*. 2003; **5**(4):269 (H24)
  - b. Electrochemical Detection on eSensor™ DNA Chips for Genotyping Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene. Y Liu, W Shi, GE Park, A Asatourians, Y Chen, **DH Farkas**, W Coty. American Association for Clinical Chemistry Meeting, July 30, 2002. Orlando, Florida.
  - c. Stable EBV transformed B lymphocyte cell lines derived from residual clinical blood for PE/QA of molecular genetic testing. JC Beck, SH Bernacki, K Snow, VM Pratt, KG Monaghan, AK Stankovic, LO Williams, KJ Matteson, FV Schaefer, M Friez, AE Shrimpton, **DH Farkas**, TW Prior, LM Wasserman, EC Cole, TT Stenzel. 2002 European Society for Human Genetics Meeting.
  - d. Results of reference testing of EBV transformed cell lines for performance evaluation and quality assurance in molecular genetic testing. LO Williams, AK Stankovic, S Bernacki, JC Beck, K Snow, VM Pratt, K Monaghan, KJ Matteson, F Schaefer, M Friez, A Shrimpton, **DH Farkas**, T Stenzel. 2002 American Society for Human Genetics Meeting. Baltimore, Maryland.

- e. Standard control lymphoblastoid cell lines for molecular genetic testing derived from residual clinical blood samples. S Bernacki, J Beck, J Herndon, A Stankovic, L. Williams, J Amos, **DH Farkas**, M Friez, FHantash, K Matteson, K Monaghan, K Muralidharan, V Pratt, T Prior, F Schaefer, A Shrimpton, E Spector, K Snow, C. Stolle, C Strom, L Wasserman, E Cole, T Stenzel. 2002 AMP Annual Meeting, November 15-17, 2002. Dallas, Texas.
5. Books written:
    - a. DNA from A to Z. AACC Press, Washington, DC, 2004.
    - b. DNA Simplified II: The Illustrated Hitchhiker's Guide to DNA. AACC Press, Washington, DC. 1999.
    - c. Molecular Pathology: Basic Methodologies and Clinical Applications: A Self-Study Guide. **DH Farkas**, AM Drevon, RG DiCarlo. AACC Press, Washington, DC, 1998.
    - d. DNA Simplified: The Hitchhiker's Guide to DNA. AACC Press, Washington DC July 1996.
  6. Books edited:
    - a. Guest Editor, *Clinics in Laboratory Medicine*, "DNA Technology." WB Saunders Company, Philadelphia, **17**(1): March 1997.
    - b. Guest Editor, *Clinics in Laboratory Medicine*, "DNA Technology." WB Saunders Company, Philadelphia, **16**(1): March 1996.
    - c. Kiechle FL, Chambers LM, Cox RS, Davis B, Davis CM, Duby M, **Farkas DH**, Fink L, Kaul KL, Wiedbrauk DL (eds.). *Patient Preparation and Specimen Handling Fascicle VII: Reference Guide to Diagnostic Molecular Pathology and Flow Cytometry*. College of American Pathologists, Northfield, Illinois, 1996.
    - d. Molecular Methods for Virus Detection. DL Wiedbrauk, **DH Farkas**, co-editors. Academic Press, San Diego, California, 1995.
    - e. So You're Going to Collect a Blood Specimen. FL Kiechle, L Chambers, R Cox, C Davis, M Duby, R Little, A Pappas, **DH Farkas**. CAP Press. 1994.
    - f. Molecular Biology and Pathology: A Guidebook for Quality Control. **DH Farkas**, editor. Academic Press, San Diego, California, 1993.
  7. Book chapters written:
    - a. Overview of Molecular Diagnostics and Application to Fragile X Syndrome. DN Feldman, BB Roa, **DH Farkas**. In: Cytogenetic Symposia, B Dunn, M Keagle and P Luplow (eds.). AMP Press, Lenexa, KS, 2004. In press
    - b. Molecular Pathology Methodologies. MJ Smith, JF Pulliam, **DH Farkas**. In: Molecular Pathology in Clinical Practice. DGB Leonard, A Bagg, A Caliendo, KL Kaul, K Snow-Bailey, V Van Deerlin, eds. Springer-Verlag, New York. 2004. In press
    - c. Thermal Cyclers. In: Laboratory Instrument Evaluation Verification and Maintenance Manual. College of American Pathologists, Northfield, IL, 1998, pg. 130-133.
    - d. Preface to *Clinics in Laboratory Medicine*, "DNA Technology in the Clinical Laboratory." WB Saunders Company, Philadelphia, 1997;**17**:xi-xii.
    - e. Quality Control Issues for the Clinical Molecular Pathologist. In: Molecular Diagnostics for the Clinical Laboratorian. WB Coleman, GJ Tsongalis, eds. Humana Press, 1997, 363-371.
    - f. Molecular Pathology. In: Encyclopedia of Molecular Biology: Fundamentals and Applications. RA Meyers, Editor-in-Chief. VCH Publishers, New York, 1996;**4**:323-333.
    - g. Preface to *Clinics in Laboratory Medicine*, "DNA Technology." WB Saunders Company, Philadelphia, 1996;**16**:xi-xii.
    - h. Considerations in Setting Up a DNA Analysis Laboratory. In: "Molecular Genetics in Diagnosis and Research." RW Allen, JP AuBuchon, eds. American Association of Blood Banks, Bethesda, Maryland, 1995, pp. 139-155.
    - g. Establishing a Clinical Molecular Biology Laboratory. **DH Farkas**. In "Molecular Biology and Pathology: A Guidebook for Quality Control." **DH Farkas**, editor. Academic Press, San Diego, California, February, 1993, pp. 1-38.

- h. Safety in the Molecular Biology Laboratory. **DH Farkas**. In "Molecular Biology and Pathology: A Guidebook for Quality Control." **DH Farkas**, editor. Academic Press, San Diego, California, February, 1993, pp. 38-50.
  - i. Specimen Procurement, Processing, Tracking, and Testing by the Southern Blot. **DH Farkas**. In "Molecular Biology and Pathology: A Guidebook for Quality Control." **DH Farkas**, editor. Academic Press, San Diego, California, February, 1993, pp. 51-75.
  - j. Quality Control of the B/T Cell Gene Rearrangement Test. **DH Farkas**. In "Molecular Biology and Pathology: A Guidebook for Quality Control." **DH Farkas**, editor. Academic Press, San Diego, California, February, 1993, pp. 77-101.
8. Other works communicating research results to scientific colleagues (peer reviewed):
- a. Molecular Diagnostics: The Best is Yet to Come. *Trends in Molecular Medicine*. 2002;**8**(6): 245.
  - b. Bioelectronic DNA Chips for the Clinical Laboratory. Letter to the Editor. *Clinical Chemistry*. 2001;**47**(10):1871-1872
  - c. On Molecular Diagnostics and Transgenic Crops. *Molecular Diagnosis*. 2000;**5**(4): 255.
  - d. Tools for Molecular Diagnostics. *IVD Technology*. 1999;**5**(6): 64-66
  - e. Molecular Diagnostics on the Menu: New Analytes Poised for the 21<sup>st</sup> Century. *Clinical Laboratory News*. Special Issue, 7.26.99: 1.
  - f. Clinical Micro Sensors Developing Point-of-Care Molecular Diagnostics. **DH Farkas**. *IVD Technology*. 1999; **5**(1): 42-43.
  - g. Clinical News Update. *Molecular Diagnosis*. 1997; **2**(3): 231-234.
  - h. Clinical News Update. *Molecular Diagnosis*. 1997;**2**(2): 157-159.
  - i. Ethical Dilemmas in Genetic Testing. K Sazama, A Caplan, N Cataldo, **DH Farkas**, M Fox, WW Grody. *Laboratory Medicine*. 1997;**28**:311-315.
  - j. Clinical News Update: Genetic Privacy Legislation. *Molecular Diagnosis*. 1997;**2**(1):83-87.
  - k. Editorial: Garbage In-Garbage Out. *Diagnostic Molecular Pathology*. 1996;**5**(4):225-226.
  - l. Today's Molecular Diagnostics: Applications and Realities. *Clinical Laboratory News*. 1996;**22**(12):10-11.
  - m. Clinical News Update: Certification for Molecular Diagnostics Laboratory Directors and Personnel. *Molecular Diagnosis*. 1996;**1**:275.
  - n. Report from the President. Informed Consent: What it Means for Researchers. **DH Farkas**, M Burritt. *Clinical Laboratory News*. 1996;**22**(9):4.
  - o. Using Molecular Markers to Manage Breast Cancer. *CAP Today*. 1996;**10**(5):41.
  - p. Clinical News Update. **DH Farkas**, DL Cooper. *Molecular Diagnosis*. 1996;**1**:75-77.
  - q. Launching a DNA Lab. *Medical Laboratory Observer*. 1995;**27** (5):42-48.
  - r. Quality Assurance Initiatives for the DNA Diagnostics Laboratory. *Medical Laboratory Observer*. 1995;**27** (6):44-49.
  - s. Adjuvant Therapy for Breast Cancer. **DH Farkas**, RM Umek. *New England Journal of Medicine*. 1994;**331**:743 (letter).
  - t. Operational Requirements of a Molecular Pathology Laboratory. DD Klosinski, SV Hunter, **DH Farkas**. *Clinical Laboratory News*. 1994;**20**(8):10.
  - u. Molecular Biology and Health Care Re-form. *Clinical Laboratory News*. 1994;**20**(7):23.
  - v. Questions and Answers on DNA Technology. **DH Farkas**, K Kaul, DD Klosinski, ER Unger. *Laboratory Medicine*. 1994;**25**:675-676.
  - w. Molecular Diagnostic Testing in 1994 and a Glimpse at the Future. *Clinical Chemistry News*. 1994;**20**(1):4.
  - x. Southern Blot Technology in the Clinical Laboratory: Quality Control and Applications. *LabMedica International*. 1993;**10**:17-24.
  - y. Molecular Biology: Practical Application in Disease Diagnosis. Contemporary Perspectives in Vaginal Infection and Health. A clinical forum for health care providers. Microprobe Corporation. September 1993.
  - z. DNA Technology in the Clinical Laboratory. **DH Farkas**, D Crisan. *Laboratory Medicine*. 1992;**23**:721-722.

- aa. DNA Technology in the Clinical Laboratory. *Biosystems Reporter*. September 1992;17:8.
- bb. The Establishment of a Clinical Molecular Biology Laboratory. *Clinical Biotechnology*. 1990;2:87-96.
- cc. The Role of Oncogenes in Carcinogenesis. DH Farkas. *Technical Community of Monsanto Newsletter*. Spring, 1988.

- 9. Other works communicating research results to general public: none

### III. Teaching Information

#### A. Didactic Course Work

- 1. Courses taught at Baylor College of Medicine
  - a. Introductory Molecular Pathology. Department of Pathology residents and fellows. One hour. January 6, 2004; January 14, 2003.
- 2. Courses taught at William Beaumont Hospital
  - a. Diagnostic Molecular Pathology. Medical Technology students. 1991-1998: three lecture hours to each class plus five laboratory hours to each class; class size ranged from six to twelve per year)
- 3. Courses taught at other institutions (hours)
  - a. 1996-1998: Faculty Coordinator, Michigan State University Certificate Program in Molecular Laboratory Diagnostics (three credit hours)
  - b. Lecture to medical technology students, Hematology course. "The B/T cell gene rearrangement test", Michigan State University, East Lansing, Michigan, November 19, 1997; November 18, 1996; November 30, 1995; December 1, 1994; November 11, 1993; December 3, 1992 (one hour each)
  - c. Moderator, Review Course for Medical Technologists' National Certification Agency Exam in Clinical Molecular Biology. R DiCarlo and A Drevon, presenters. Association for Molecular Pathology Annual Meeting, San Diego, California, November 13, 1997 (three hours)
  - d. Introduction, "Review of Molecular Biology" course, presented by R DiCarlo and A Drevon at the Michigan Society of Clinical Laboratory Scientists' Annual Meeting in Troy, Michigan, April 11, 1997 (three hours)
  - e. Molecular Methods in Diagnostic Medicine. A lecture to 150 Genetics undergraduates at the University of Michigan-Flint. April 15, 1994 (one hour)
  - f. Lecture to graduate faculty and students, Introduction to Research course. "HER-2/*neu* oncogene amplification as a prognostic indicator in breast cancer", Michigan State University, East Lansing, Michigan, November 12, 1992 (one hour)
- 3. Courses expected to be taught at Baylor College of Medicine
  - a. Diagnostic Molecular Pathology Technologies and Applications

#### B. Non-didactic teaching

- 1. Resident training (including clinical chemistry and blood bank fellows)
  - a. William Beaumont Hospital (1991-1998): two to three residents and fellows per year for two to four weeks per rotation with time spent averaging one to two hours per day during rotation.
  - b. Saint Barnabas Medical Center (1989-1991): two to three residents per year for one to two weeks per rotation with time spent averaging one to two hours per day during rotation.
- 2. Graduate student training: none
- 3. Non-didactic teaching expected at Baylor College of Medicine
  - g. In laboratory training of molecular genetic pathology fellows from July 1, 2003-February 29, 2004 and July 1-October 31, 2004

#### C. Lectures: See II. B. 4.

**D.** Visiting professorships: none

**IV. Medical and Service Information**

**A. Patient Care Responsibilities**

**1. Department-wide**

**a.** 2003-2004: Molecular pathology support within the Department of Pathology (Baylor College of Medicine and The Methodist Hospital)

**b.** 1991-1998: Molecular pathology support of different sections department-wide in consultation for differential diagnoses, particularly cytogenetics (different department: Anatomic Pathology Department), microbiology, virology, hematology, anatomic pathology (different department: Anatomic Pathology Department) and coagulation (William Beaumont Hospital)

**2. Section**

**a.** 2003-2004: Medical Director, Molecular Diagnostics Laboratory, Department of Pathology, The Methodist Hospital/Baylor College of Medicine, Houston, Texas.

**b.** 1991-1998: Co-director, Molecular Probe Laboratory, Department of Clinical Pathology, William Beaumont Hospital, Royal Oak, Michigan. Established and organized departmental molecular diagnostics laboratory. Developed, implemented, and performed DNA-based molecular diagnostic assays, with associated administration, quality control, quality assurance and education. Tests in support of diagnoses in microbiology, virology, coagulation, genetic disease, solid tumors, and hematology-oncology.

**c.** 1989-1991: Section Chief, Diagnostic Molecular Pathology, Department of Pathology, Saint Barnabas Medical Center, Livingston, New Jersey. Established and organized clinical molecular biology laboratory; developed and implemented DNA-based molecular diagnostic assays, principally for hematology-oncology and breast cancer diagnostics.

**B. Clinical laboratory responsibilities**

**1.** The Methodist Hospital: established and organized departmental molecular diagnostics laboratory; developing, implementing, and performing DNA-based molecular diagnostic assays, with associated administration, quality control, quality assurance and education

**2.** William Beaumont Hospital: oversaw day to day operations of laboratory; administered quality assurance program; reviewed all patient test results and associated quality control before results reporting; prepared all aspects of laboratory procedure manual; maintained and readied laboratory for annual CAP or self-inspection; oversaw growth of laboratory that signed out five test results in 1991 (laboratory “opened” in December of that year) to one that signed out approximately 18,000 test results in 1998.

**3.** Saint Barnabas Medical Center: similar to IV. B. 2 on a smaller scale for a shorter time.

**C. National education or voluntary health organization participation: not applicable**

**D. Administrative assignments**

**1. Department administration, committees, etc.**

**a.** Host, Grand Rounds Lecture Series: Eric Hsi (2003); Karen Kaul (2003); Stephen Thibodeau (2003); Mark Stoler (2004)

**b.** 2002: Search committee for Director of Hematopathology, Department of Pathology, Baylor College of Medicine

**c.** 1991-1994: Member, William Beaumont Hospital Research Institute Common Use Committee

**d.** Responsible for all quality control administration and quality assurance programs within the Molecular Diagnostics Laboratory

**2. College, School or University administration, committees, etc.**

**a.** Involved with medical technology school admissions process, William Beaumont Hospital, 1993-1998

E. Other pertinent information not given above (see Appendices 1 and 2)



## **Appendix One: CONTINUING EDUCATION**

Association for Molecular Pathology Annual Meeting. Orlando, Florida, November 21-23, 2003. 8.25 Category I Credits

College of American  
American Association for Clinical Chemistry Annual Meeting. Philadelphia, Pennsylvania, July 2003. 4  
ACCENT Credit Hours

Association for Molecular Pathology Annual Meeting. Dallas, Texas, November 15-17, 2002. 13.5 Category I Credits

Fourth Annual Pathology Compliance and Coding Seminar. Baylor College of Medicine. Houston, Texas, November 4, 2002. Two Category I Credits

American Association for Clinical Chemistry Annual Meeting. Orlando, Florida, July 2002. 12 ACCENT Credit Hours

AACC Pharmacogenomics Conference. Philadelphia, Pennsylvania, May 9-10, 2002. 10.5 ACCENT Credits Hours.

Association for Molecular Pathology Annual Meeting. Philadelphia, Pennsylvania, November 16-18, 2001. 13.75 Category I Credits

AACC "San Diego" Conference: "Cool Tools-New Technologies for Molecular Diagnostics." San Diego, California, November 8-10, 2001. 17 ACCENT credit hours

College of American Pathologists Annual Meeting. Philadelphia, Pennsylvania, October 22, 2001. 3.5 Category I Credits

American Association for Clinical Chemistry Annual Meeting. Chicago, Illinois, July 2001. 5.5 Category I Credits

International Society for Analytical and Molecular Morphology Annual Meeting. Faculty member. Santa Fe, New Mexico, February 2-7, 2001. 8.5 lecture hours

AACC Arnold O. Beckman Conference: "The Clinician and Laboratorian-Dynamic Transitions." Newport Beach, California, February 11-12, 2001. 9 ACCENT credit hours

Association for Molecular Pathology Annual Meeting. Denver, Colorado. November 10-12, 2000. 13 Category I Credits

American Association for Clinical Chemistry Annual Meeting. San Francisco, California, July 2000. 6.25 Category I Credits

International Society for Laboratory Hematology Conference. Banff, Alberta, Canada, April 12-16, 2000. 18 Category I Credits

Association for Molecular Pathology Annual Meeting. St. Louis, Missouri, November 5-7, 1999. 12.5 Category I Credits

College of American Pathologists Conference XXXIV. Molecular Pathology: Role in Improving Patient Outcome. Bethesda, Maryland, February 26-28, 1999. 17.5 CME/CMLE Credit Hours

Association for Molecular Pathology Annual Meeting. Crystal City, Virginia, November 6-8, 1998. 18 Category I Credits

American Association for Clinical Chemistry Annual Meeting. Chicago, Illinois, August 1998. 7.5 Category I Credits

William Beaumont Hospital's 7<sup>th</sup> annual seminar on DNA Technology in the Clinical Laboratory: Wm. Beaumont Hospital, Royal Oak, Michigan, March 26-28, 1998. 19 Category I CME credits

Association for Molecular Pathology Annual Meeting. San Diego, California, November 13-15, 1997. 14.75 Category I Credits

American Association for Clinical Chemistry/Association for Molecular Pathology meeting on Viral Load Testing. Dallas, Texas, September 13, 1997. 6.5 Category I Credits

American Association for Clinical Chemistry Annual Meeting. Atlanta, Georgia, July 1997. 9 Category I Credits

Clinical Ligand Assay Society. Back to Basics-Laboratory Without Walls. Romulus, Michigan, April 30, 1997. Three credit hours

William Beaumont Hospital's 6th annual seminar on DNA Technology in the Clinical Laboratory: William Beaumont Hospital, Royal Oak, Michigan, March 14-15, 1997. 13 Category I CME credits

American Association for Clinical Chemistry Local Michigan Section Meeting: Update on Tumor Markers, Ann Arbor, Michigan, March 6, 1997. 3.5 Category I Credits

Weekly Clinical Pathology seminar, William Beaumont Hospital, Royal Oak, Michigan. 17 Category I CME credits for 1996

Association for Molecular Pathology Annual Meeting. Baltimore, Maryland, November 15-17, 1996. Nine Category I Credits

Molecular Diagnostics in Clinical Laboratory Medicine. Five Category I Credits-Category A1 for the Recognition Award for Continuing Medical Laboratory Education. Winthrop-University Hospital, Mineola, New York, October 25, 1996

The Institute for Continuing Healthcare Education. Molecular Diagnostics: Promises and Realities. Rosemont, Illinois, October 7, 1996. Six Category I Credits-Category A1 for the Recognition Award for Continuing Medical Laboratory Education (American Society of Clinical Pathologists)

American Association for Clinical Chemistry Annual Meeting. Chicago, Illinois, July 1996. 13 Category I Credits

University at Buffalo School of Medicine and Biomedical Sciences-13th Convocation on Immunology. Buffalo, New York, June 1-5, 1996. 18 hours of Category I Credit

Weekly Clinical Pathology seminar, William Beaumont Hospital, Royal Oak, Michigan. 22 Category I CME credits for 1995

Tenth annual AACC-San Diego Conference on Nucleic Acids. San Diego, California, November 16-18, 1995. Twenty Category I Credits

Annual Association for Molecular Pathology Meeting, Minneapolis, Minnesota, November 10-12, 1995. 18 Category I Credits

CAP inspection of DMC University Laboratories. Detroit, Michigan, November 6, 1995. Seven Category I Credits

How Can Laboratories Help Hospitals Survive? American Association for Clinical Chemistry Videoconference, Royal Oak, Michigan, October 26, 1995. 2 Category I Credits

“Molecular Diagnostics”, a symposium presented at the annual Clinichem Meeting of the AACC. Teaneck, New Jersey, October 14, 1995. 2 Category I Credits

American Association for Clinical Chemistry Local Michigan Section Meeting: New Solutions to Old Problems, Romulus, Michigan, September 14, 1995. 4 Category I Credits

American Association for Clinical Chemistry Annual Meeting: Anaheim, California, July 1995. 8 Category I Credits

1995 NCCLS Annual Meeting and Education Program: “The Winds of Change-Moving Ahead, at what Cost?” Chicago, Illinois, March 30-31, 1995. Nine Accent Category I Credits

Weekly Clinical Pathology seminar, William Beaumont Hospital, Royal Oak, Michigan. 22 Category I CME credits for 1994

San Diego Conference, “The Genetic Revolution,” San Diego, California, November 17-19, 1994. 12 hours

Third annual meeting on Molecular Pathology. Universities Associated for Research and Education in Pathology. November 11-13, 1994, Rockville, Maryland, 20 hours

American Association for Clinical Chemistry, Michigan Section Meeting: September 22, 1994. 2 Category I Credit. Health Care Reform Update/Lab Licensure in Michigan

Roche Grand Rounds Presentation on the Polymerase Chain Reaction. Detroit, Michigan, September 21, 1994, One hour

American Association for Clinical Chemistry Annual Meeting: New Orleans, Louisiana, July 1994. 11 Category I Credits

Participant in workshop on molecular HLA typing. Gen-Trak, Inc., Plymouth Meeting, Pennsylvania, June 13-14, 1994; 15 hours

Workshop at the Annual Meeting of the American Society of Clinical Pathologists. “Quality Control Measures and Quality Assurance Programs in the Molecular Pathology Laboratory.” Seattle, Washington, April 9, 1994. 3 Category I CME credits

William Beaumont Hospital's 3rd annual seminar on DNA Technology in the Clinical Laboratory: Wm. Beaumont Hospital, Royal Oak, Michigan, March 25, 1994. 9 Category I CME credits

Short Course, Annual Meeting of the United States and Canadian Academy of Pathology. “Quality Control in the Clinical Molecular Pathology Laboratory.” San Francisco, California, March 17, 1994. 3 Category I CME credits

Weekly Clinical Pathology seminar, William Beaumont Hospital, Royal Oak, Michigan. 30 Category I CME credits for 1993

Eighth annual San Diego Conference: Beyond DNA Probes (American Association for Clinical Chemistry). San Diego, California, November 17-20, 1993

Association of Clinical Scientists 1993 Fall Meeting, Toledo, Ohio; seven hours ACCME Category I CME credits

American Association for Clinical Chemistry Annual Meeting: New York, New York, July 1993. 11 Category I Credits

American Society of Clinical Pathologists Teleconference. Setting up a Molecular Diagnostics Laboratory. May 25, 1993, 1 CME credit

American Association for Cancer Research Annual Meeting, Orlando, Florida, May 1993

The Next Generation of Testing: Basic and Clinical Molecular Diagnostic Applications. April 3, 1993, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Six credit hours-Category I (AMA)

“Molecular Assistance for Oncologists,” lecture to meeting of the Crossroads chapter of the Chemical Ligand Assay Society, University of Louisville, Louisville, Kentucky, March 13, 1993.

“DNA Technology in the Clinical Laboratory.” William Beaumont Hospital, Royal Oak, Michigan, March 1, 1993. 6 CME credits

Moderator, “Molecular Aspects of Histocompatibility Testing”, a one day symposium by the Organ Procurement Agency of Michigan, Detroit, Michigan, January 22, 1993

Weekly Clinical Pathology seminar, William Beaumont Hospital, Royal Oak, Michigan. 38 Category I CME credits for 1992

American Society of Clinical Pathologists Teleconferences. 1992. 4 CME Credits

“Federal Regulation of Laboratories: Changing Groundrules for the 1990s,” sponsored by the Michigan Health Care Institute, Lansing, Michigan, August 28, 1992

American Association for Clinical Chemistry Annual Meeting: Chicago, Illinois, July 1992. 20 Category I Credits

American Association for Cancer Research Annual Meeting: May 1992, San Diego, California

Michigan Society of Pathologists-February 22, 1992: (i) Barrett’s Esophagus and (ii) Molecular Biology of Colorectal Cancer. Two Category I credits

“DNA Technology in the Clinical Laboratory,” a one day Molecular Pathology Seminar. William Beaumont Hospital, Royal Oak, Michigan, January 31, 1992. 6 CME credits

Weekly Clinical Pathology seminar, William Beaumont Hospital, Royal Oak, Michigan. 19 Category I CME credits for 1991

American Society of Clinical Pathologists Teleconferences. 1991. 1 CME Credit

“Variegated Patterns of Clinical Pathology,” William Beaumont Hospital, Royal Oak, Michigan, August 1991

American Association for Clinical Chemistry Annual Meeting: Washington DC, July 1991. 23 Category I Credits

DNA Workshop, (Bio-Synthesis) at the University of North Texas, Denton, Texas, July 1991

American Society of Clinical Pathologists Teleconferences. 1990. 4 CME Credits

Twelfth Annual Conference on Clinical Laboratory Molecular Analysis, Scripps Clinic and Research Foundation, La Jolla, California, February 7-9, 1990. 21 credit hours-Category I

American Society of Clinical Pathologists Teleconferences. 1989. 9 CME Credits

## Appendix Two:

### Abstracts and associated presentations made greater than three years ago:

1. Chipping Away: What's New in Molecular Technologies for Clinical Laboratories. *Clinical Chemistry*, **49**:S12, 1999.
2. Detection of Circulating PSA mRNA Positive Cells in Patients with Prostate Adenocarcinoma. D Crisan, B O' Malley, **DH Farkas**. Abstract published and presented as a poster at the Cambridge Symposia: Genetic Approaches to Breast and Prostate Cancer, Lake Tahoe, California, March 22-27, 1997.
3. The Use of Molecular Diagnostic Methods for Lymphoma Staging in Bilateral Bone Marrow Biopsies. T Murphy, D Crisan, **D Farkas**. Presented at the 5th Annual Association for Molecular Pathology Meeting, Baltimore, Maryland, November 15-17, 1996. Abstract published in the *American Journal of Pathology*, **149**:1781, 1996.
4. Novel Chemiluminescent Substrate and Probe Systems for the Identification of Genotypes. LV Reddy, **DH Farkas**, H Akhavan-Tafti, R DiSilva, RS Handley, AP Schaap. Poster presented at the 11th Annual American Association for Clinical Chemistry San Diego Conference, November 21-23, 1996.
5. Detection of Hepatitis C Virus by Reverse Transcriptase Polymerase Chain Reaction; Clinical use for Diagnostics and Monitoring of Interferon Therapy. JG Buck, D Crisan, **DH Farkas**. *Clinical Chemistry* 1995;**41**:1685-1686.
6. Detection of Hepatitis C Virus by Reverse Transcriptase Polymerase Chain Reaction; Clinical use for Diagnostics and Monitoring of Interferon Therapy. JG Buck, D Crisan, **DH Farkas**. Poster presented at the 10th Annual American Association for Clinical Chemistry San Diego Conference, November 16-18, 1995.
7. Molecular Analysis in a Patient with Waldenstrom's Macroglobulinemia Reveals a Rare Case of Biclinality. R Schulz, D Crisan, **DH Farkas**. *Clinical Chemistry*. 1994; **40** (12):2335-2336.
8. Molecular Analysis in a Patient with Waldenstrom's Macroglobulinemia Reveals a Rare Case of Biclinality. R Schulz, D Crisan, **DH Farkas**. Poster presented at the American Association for Clinical Chemistry San Diego Conference, The Genetic Revolution, November 17-19, 1994.
9. Laboratory Analysis for HER-2/*neu* Gene Amplification and Protein Overexpression. **DH Farkas**, RM Umek. Poster presented at Molecular Pathology 1994-A Workshop in Molecular Diagnostics, sponsored by Universities Associated for Research and Education in Pathology, November 11-13, 1994.
10. Discrepant Morphologic Features in Bone Marrow Involvement by Malignant Lymphomas: Use of Gene Rearrangement Patterns for Diagnosis. D Crisan, JC Mattson, **DH Farkas**. Poster presentation at the AACC Michigan Section Spring Meeting, Frankenmuth, Michigan, May 20, 1994.
11. Operational Requirements of a Molecular Pathology Laboratory. D Klosinski, SV Hunter, **DH Farkas**. *Clinical Chemistry*. 1994;**40** (4):658.
12. Discrepant Morphologic Features in Bone Marrow Involvement by Malignant Lymphomas: Use of Gene Rearrangement Patterns for Diagnosis. D Crisan, JC Mattson, **DH Farkas**. *American Journal of Clinical Pathology*. 1994;**101** (3):389-390.
13. Quantitation of HER-2/*neu* Gene Copy Number in Breast Tumor Derived Deoxyribonucleic Acid Samples. *Annals of Clinical and Laboratory Science*. 1994;**24**(2):188.
14. Molecular Diagnostic Testing for Lymphomas in Body Fluids. DL Schultz, D. Crisan, **DH Farkas**, RC Hankin, EG Bernacki, JC Chen. *Annals of Clinical and Laboratory Science*. 1994;**24**(2):191.
15. Operational Requirements of a Molecular Pathology Laboratory. D Klosinski, SV Hunter, **DH Farkas**. Poster presented at the American Association for Clinical Chemistry San Diego Conference, Beyond DNA Probes, November 18-20, 1993.

16. Designing clinical experiences for laboratory sciences students and technologists in molecular pathology. D Klosinski, N Matta, S Hunter, **DH Farkas**, D Crisan, R Hankin. *Clinical Laboratory Science*. 1993;**6**:147.
17. Bone marrow involvement in extra-nodal lymphomas: use of B/T cell gene rearrangements for diagnosis. D Crisan, **DH Farkas**, JC Mattson, N Matta. American Society for Clinical Pathology Fall Meeting, Orlando, Florida, October 1993.
18. Implementation of a new test under CLIA '88: Fragile X detection by DNA analysis. **DH Farkas**, D Crisan, N Matta, E Carr, A Al-Saadi. Association of Clinical Scientists' Spring Meeting, Newport, Rhode Island, May 13, 1993.
19. Bone marrow biopsy imprint preparations in molecular diagnostic tests. D Crisan, **DH Farkas**, E Carr, N Matta, MJ Anstett. *Annals of Clinical and Laboratory Science*. 1993;**23**:302-303.
20. Implementation of a new test under CLIA '88: Fragile X detection by DNA analysis. **DH Farkas**, D Crisan, N Matta, E Carr, A Al-Saadi. *Annals of Clinical and Laboratory Science*. 1993;**23**:305-306.
21. Bone marrow biopsy imprint preparations in molecular diagnostic tests. D Crisan, **DH Farkas**, E Carr, N Matta, MJ Anstett. Association of Clinical Scientists' Spring Meeting, Newport, Rhode Island, May 13, 1993.
22. Bone Marrow Involvement in Extra-nodal Lymphomas: Use of B/T-Cell Gene Rearrangements for Diagnosis, D Crisan, DH Farkas, JC Mattson, N Matta. *American Journal Clinical Pathology*. 1993;**100**(3):339.
23. Detection of the follicular lymphoma-specific chromosomal translocation involving the *Bcl-2* oncogene by nucleic acid hybridization and the polymerase chain reaction (PCR): a comparison. MJ Anstett, E Carr, N Matta, **DH Farkas**, D Crisan. 25th annual American Association for Clinical Chemistry Oak Ridge Conference, Knoxville, Tennessee, April 22, 1993.
24. Detection of BCR gene rearrangements and early myeloid markers in CML and acute leukemias by mRNA analysis from hematology smears. D Crisan, **DH Farkas**, N Matta, E Carr, MJ Anstett. Controversies in Bone Marrow Transplantation Conference, San Antonio, Texas, April 21, 1993.
25. DNA Technology in the Clinical Laboratory. *Clinical Chemistry*. 1992;**38** (6):1139-40.
26. Inhibition of Transient Gene Expression with Herpesvirus Genes. T Block, R Jordan, **DH Farkas**, RG Hughes. American Society for Virology. London, Ontario. 1989.
27. Inhibition of Transient Gene Expression with HSV-1 Subgenomic Fragments. T Block, R Jordan, **DH Farkas**, A Lange, R Hughes. 13th International Herpesvirus Workshop. Irvine, California. 1988.
28. Herpes simplex Virus Antitransformation Sequences. 12th International Herpesvirus Workshop. T Block, **DH Farkas**, R Jordan, R Hughes. Philadelphia, Pennsylvania. 1987.
29. American Society for Virology Annual Meeting-University of California at Santa Barbara. Herpes Simplex Virus Sequences that Inhibit DNA-Mediated Gene Transfer. June 22, 1986.